Published in Endocrinology on February 19, 2004
FGF-21 as a novel metabolic regulator. J Clin Invest (2005) 10.69
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes (2008) 5.62
FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A (2009) 3.99
Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev (2013) 3.74
FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (2011) 3.16
Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev (2012) 2.91
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med (2015) 2.86
Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 2.67
Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care (2009) 2.15
Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology (2009) 2.08
FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab (2011) 1.97
A new era in brown adipose tissue biology: molecular control of brown fat development and energy homeostasis. Annu Rev Physiol (2013) 1.86
Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem (2011) 1.62
Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev (2014) 1.58
Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J Clin Invest (2015) 1.56
Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nat Med (2016) 1.45
Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One (2012) 1.44
Bile acid metabolism and signaling. Compr Physiol (2013) 1.42
A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care (2013) 1.38
FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One (2011) 1.35
Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep (2011) 1.30
Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One (2012) 1.30
FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem (2009) 1.26
The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice. BMC Med Genomics (2008) 1.23
Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab (2014) 1.23
Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem (2009) 1.22
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci U S A (2009) 1.22
Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2012) 1.20
Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer (2012) 1.19
FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem (2009) 1.19
FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest (2013) 1.18
C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem (2008) 1.16
Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology (2012) 1.15
Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol (2015) 1.12
Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol (2013) 1.10
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res (2009) 1.08
FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol (2011) 1.08
Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol (2010) 1.08
Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med (2015) 1.06
Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem (2012) 1.05
Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog (2009) 1.05
Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci U S A (2010) 1.05
Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis. Aging (Albany NY) (2009) 1.04
Brown adipose tissue: development, metabolism and beyond. Biochem J (2013) 1.03
Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res (2013) 1.02
Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease. Mol Pharm (2007) 1.01
FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Commun (2015) 0.99
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. Diabetes (2013) 0.97
Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol (2012) 0.96
Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. Am J Physiol Gastrointest Liver Physiol (2011) 0.96
Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. Biochim Biophys Acta (2014) 0.96
Low vitamin D status is associated with nonalcoholic Fatty liver disease independent of visceral obesity in Korean adults. PLoS One (2013) 0.92
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J Lipid Res (2009) 0.92
The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes (Lond) (2015) 0.92
Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. PLoS One (2013) 0.92
Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis (2013) 0.91
Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond) (2014) 0.91
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov (2015) 0.90
Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress. Nutr Metab (Lond) (2012) 0.89
Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One (2012) 0.89
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun (2015) 0.89
A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS One (2011) 0.87
Bile Acids as Hormones: The FXR-FGF15/19 Pathway. Dig Dis (2015) 0.86
Genome-wide copy number variations inferred from SNP genotyping arrays using a Large White and Minzhu intercross population. PLoS One (2013) 0.86
Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes (Lond) (2015) 0.86
Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis. Semin Cell Dev Biol (2015) 0.86
Therapeutic prospects of metabolically active brown adipose tissue in humans. Front Endocrinol (Lausanne) (2011) 0.86
Modulation of metabolic syndrome by fibroblast growth factor 19 (FGF19)? Endocrinology (2004) 0.86
Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response. Mol Metab (2015) 0.86
Fibroblast growth factor (FGF) signaling in development and skeletal diseases. Genes Dis (2014) 0.85
Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care (2013) 0.85
Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. Cancer Metab (2013) 0.85
Serum levels of fibroblast growth factor 19 are inversely associated with coronary artery disease in chinese individuals. PLoS One (2013) 0.85
Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease. Adv Nutr (2014) 0.85
The heteromeric organic solute transporter, OSTα-OSTβ/SLC51: a transporter for steroid-derived molecules. Mol Aspects Med (2013) 0.84
Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J Biol Chem (2014) 0.84
Nuclear receptors and metabolism: from feast to famine. Diabetologia (2014) 0.84
Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res (2012) 0.84
Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Sci Rep (2015) 0.84
Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1. J Biol Chem (2011) 0.83
Myocardial lysyl oxidase regulation of cardiac remodeling in a murine model of diet-induced metabolic syndrome. Am J Physiol Heart Circ Physiol (2009) 0.83
Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex. EBioMedicine (2015) 0.83
Mechanisms for increased expression of cholesterol 7alpha-hydroxylase (Cyp7a1) in lactating rats. Hepatology (2010) 0.83
Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. Mol Endocrinol (2015) 0.82
Enhanced in vitro refolding of fibroblast growth factor 15 with the assistance of SUMO fusion partner. PLoS One (2011) 0.82
Fibroblast growth factor 19 entry into brain. Fluids Barriers CNS (2013) 0.82
Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta Pharm Sin B (2015) 0.82
Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application. PLoS One (2012) 0.82
Role of bile acids in the regulation of the metabolic pathways. World J Diabetes (2016) 0.81
FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes. Obes Surg (2016) 0.81
The structural biology of the FGF19 subfamily. Adv Exp Med Biol (2012) 0.81
Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS One (2013) 0.81
Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta (2016) 0.81
Fibroblast Growth Factor Signaling in Metabolic Regulation. Front Endocrinol (Lausanne) (2016) 0.80
Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho. J Biol Chem (2011) 0.79
Serum fibroblast growth factor 19 is decreased in patients with overt hypothyroidism and subclinical hypothyroidism. Medicine (Baltimore) (2016) 0.79
Brown Adipose YY1 Deficiency Activates Expression of Secreted Proteins Linked to Energy Expenditure and Prevents Diet-Induced Obesity. Mol Cell Biol (2015) 0.78
Molecular Pathogenesis of NASH. Int J Mol Sci (2016) 0.78
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res (2005) 4.94
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest (2006) 3.75
Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature (2010) 3.52
Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med (2003) 3.50
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 3.42
Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology (2002) 3.21
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res (2009) 2.65
Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses. J Clin Endocrinol Metab (2009) 2.58
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem (2007) 2.55
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab (2009) 2.35
Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med (2008) 2.29
Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One (2010) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A (2009) 1.89
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem (2005) 1.87
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J Lipid Res (2012) 1.79
PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (2010) 1.75
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A (2007) 1.73
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood (2014) 1.71
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem (2005) 1.69
In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics (2002) 1.66
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. Am J Physiol Endocrinol Metab (2013) 1.58
ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther (2012) 1.55
Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol (2012) 1.50
Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood (2012) 1.43
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Synchronizing clinician engagement and client motivation in telephone counseling. Qual Health Res (2004) 1.40
Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation. J Biol Chem (2004) 1.39
Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol (2010) 1.38
Increased expression of receptors for orexigenic factors in nodose ganglion of diet-induced obese rats. Am J Physiol Endocrinol Metab (2009) 1.37
TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell (2012) 1.34
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab (2009) 1.31
Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation (2006) 1.29
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
Vascular endothelial-junctional adhesion molecule (VE-JAM)/JAM 2 interacts with T, NK, and dendritic cells through JAM 3. J Immunol (2002) 1.26
Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med (2013) 1.25
Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat Immunol (2013) 1.24
Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology (2008) 1.24
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res (2012) 1.23
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res (2012) 1.16
Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice. Physiol Genomics (2002) 1.16
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods (2008) 1.11
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood (2007) 1.11
Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One (2012) 1.09
Leucine and protein metabolism in obese Zucker rats. PLoS One (2013) 1.07
Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci U S A (2002) 1.07
Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs (2011) 1.06
Tobacco dependence: adolescents' perspectives on the need to smoke. Soc Sci Med (2003) 1.06
Cutting edge: novel human dendritic cell- and monocyte-attracting chemokine-like protein identified by fold recognition methods. J Immunol (2006) 1.04
Opportunities to learn and barriers to change: crack cocaine use in the Downtown Eastside of Vancouver. Harm Reduct J (2008) 1.04
Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J Biol Chem (2002) 1.03
Characterization of Tusc5, an adipocyte gene co-expressed in peripheral neurons. Mol Cell Endocrinol (2007) 1.03
High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol (2007) 1.03
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res (2013) 1.02
Contributions of adipose tissue architectural and tensile properties toward defining healthy and unhealthy obesity. Am J Physiol Endocrinol Metab (2013) 1.02
PQN and DQN: algorithms for expression microarrays. J Theor Biol (2006) 1.01
Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol (2002) 1.01
Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis. Cancer Res (2009) 0.99
Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol (2013) 0.98
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther (2008) 0.98
Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog (2013) 0.98
A modular platform for the rapid site-specific radiolabeling of proteins with 18F exemplified by quantitative positron emission tomography of human epidermal growth factor receptor 2. J Med Chem (2009) 0.97
VEGF-C mediates cyclic pressure-induced endothelial cell proliferation. Physiol Genomics (2002) 0.97
Gamma-synuclein is an adipocyte-neuron gene coordinately expressed with leptin and increased in human obesity. J Nutr (2008) 0.97
Mass Screening for Severe Problem Behavior among Infants and Toddlers In Peru. J Ment Health Res Intellect Disabil (2012) 0.96
Efficacy of a smoking-cessation intervention for elective-surgical patients. Res Nurs Health (2004) 0.96
Hypoxia and oxygenation induce a metabolic switch between pentose phosphate pathway and glycolysis in glioma stem-like cells. Acta Neuropathol (2013) 0.96
Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs (2012) 0.95